On 3 June 2026, the International Council for Harmonisation (ICH) adopted the final version of ICH E6 (R3) Annex 2, marking another significant milestone in the evolution of Good Clinical Practice (GCP).
For many organisations, the release of Annex 2 raises two important questions: what has changed since the draft version, and is existing GCP training still sufficient?
What is Annex 2?
Annex 2 supplements the ICH E6 (R3) Principles and Annex 1 by providing additional Good Clinical Practice considerations for clinical trials that incorporate decentralised elements, pragmatic approaches and real-world data (RWD).
The guideline recognises that clinical research is changing rapidly. Remote visits, digital health technologies, home healthcare services, electronic health records and real-world data sources are becoming increasingly common. While these approaches offer significant opportunities to improve trial accessibility and efficiency, they also introduce new challenges relating to oversight, participant safety, data integrity, privacy and regulatory compliance.
Rather than replacing traditional GCP principles, Annex 2 explains how those principles should be applied when modern trial methodologies are used.
Has Anything Changed Since the Draft Version?
The overall structure and intent of Annex 2 remain largely unchanged from the draft version released for public consultation. However, the final version adopted on 3 June 2026 contains a number of important clarifications and enhancements.
The most significant changes relate to real-world data. The final guidance provides much clearer expectations regarding sponsor oversight, data governance, access to individual-level data and source records, and the arrangements that should be in place when data are owned or controlled by third parties. Greater emphasis is also placed on ensuring that real-world data are fit for purpose, including consideration of data reliability, relevance, provenance, traceability, bias and generalisability.
The final version also strengthens guidance relating to oversight of healthcare professionals working within usual clinical practice, direct-to-participant investigational product supply, participant-centred trial design and the management of safety information collected from multiple sources.
For organisations that have already reviewed the draft, the final guidance is not a complete rewrite. However, it provides greater clarity around regulatory expectations and introduces several areas that may be particularly relevant during audits and inspections.
Why Was Annex 2 Needed?
Traditional GCP guidance was developed when most clinical trials were conducted entirely within investigator sites. Today’s research environment is very different.
Many studies now involve remote assessments, telemedicine visits, wearable devices, mobile applications, home nursing services and the use of healthcare data that were originally collected for purposes other than the clinical trial itself.
These approaches can reduce participant burden, improve recruitment and retention, increase diversity and generate more representative data. However, they also create additional considerations around oversight, data quality, cybersecurity, privacy, informed consent and participant protection.
Annex 2 provides a framework for managing these challenges while maintaining the core principles of GCP.
Is My GCP Certificate Enough?
This is one of the most common questions being asked following the release of Annex 2.
The answer depends largely on the type of clinical trials you support.
If your role is limited to traditional site-based clinical trials, your existing GCP training may cover many of the core principles required for your day-to-day responsibilities. However, Annex 2 introduces additional expectations and practical considerations for decentralised clinical trials, pragmatic trial designs, digital health technologies and real-world data that are not typically explored in detail during standard GCP training.
As Annex 2 now forms part of the ICH E6 (R3) Good Clinical Practice framework, organisations should consider whether personnel involved in these modern trial approaches have received appropriate training on the additional requirements relevant to their role.
During audits and inspections, organisations may be expected to demonstrate that staff are trained and competent in the current GCP requirements applicable to the activities they perform. For teams working with decentralised trials, remote technologies, real-world data or innovative trial designs, understanding Annex 2 is becoming increasingly important.
What Should Organisations Do Next?
The release of Annex 2 should prompt organisations to review their current training programmes and assess whether staff involved in modern clinical trial methodologies have sufficient knowledge of the new guidance.
Sponsors, CROs, investigators, study coordinators, clinical operations teams, quality professionals and regulatory personnel should all consider how Annex 2 applies to their roles and whether additional training is required to support compliance and inspection readiness.
The guideline does not change the fundamental principles of Good Clinical Practice. Instead, it provides practical guidance on how those principles should be applied in an increasingly digital, decentralised and data-driven research environment.
For professionals looking to understand the practical application of the new guidance, our Implementing ICH GCP E6 (R3) Annex 2 course provides a comprehensive overview of the final Annex 2 requirements, including decentralised clinical trials, pragmatic trial designs, digital health technologies, real-world data, sponsor and investigator responsibilities, and the additional considerations introduced by the final guidance. You can learn more about the course here: https://integrityclinicalcompliance.com/courses/good-clinical-practice-e6r3-annex-2/
